Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a single arm, multi-center clinical trial. The goal of this clinical trial is to evaluate the efficacy, safety and biomarkers of Tafolecimab combined with Sintilimab and Chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). Tafolecimab is a recombinant fully humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK-9), which can reduce low-density lipoprotein-C levels and increase the expression level of major histocompatibility complex class I (MHC-I) on tumor cells. Sintilimab is a fully humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat, ogólny stan zdrowia pozwalający na leczenie (skala 0-1)
- •Potwierdzony rozpoznaniem zaawansowany rak płuc z małymi komórkami
- •Dotychczas bez wcześniejszego leczenia systemowego tego raka
- •Co najmniej jeden guz do zmierzenia wg standardowych kryteriów
- •Spodziewana przeżywalność co najmniej 12 tygodni
- •Prawidłowa funkcja narządów wewnętrznych
✗ Disqualifies
- •Poprzednie leczenie systemowe raka płuc z małymi komórkami
- •Mieszany typ raka lub transformacja do innego rodzaju
- •Uczestnietwo w innym badaniu klinicznym w ostatnich 4 tygodniach
- •Aktywne przerzuty w mózgu powodujące objawy
- •Poważne choroby sercowo-naczyniowe
- •Aktywne zapalenie wątroby lub HIV
- •Czynne choroby autoimmunologiczne lub niekontrolowane choroby
- •Ciąża lub karmienie piersią
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Changsha, China
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science
Jinan, China
Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
Hangzhou, China
First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China
Trial contact
Yang Xia, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.